Compare AU

Compare CURE vs. IHD

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the iShares S&P/ASX Div Opportunities Esg Screened ETF (IHD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

IHD

Popularity

Low

Low

Pearlers invested

83

27

Median incremental investment

$619.50

$644.56

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$1,357.92

Average age group

> 35

> 35


Key Summary

CURE

IHD

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

IHD.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The ETF currently has 305.98m in AUM and 51 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of 50 ASX listed stocks that offer high dividend yields while meeting diversification, profitability and tradability requirements as well as being screened for sustainability considerations

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

RIO TINTO LTD (9.87 %)

FORTESCUE LTD (8.72 %)

WESTPAC BANKING CORPORATION CORP (8.18 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Financials (42.51 %)

Materials (22.84 %)

Industrials (13.44 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Australia (99.25 %)

New Zealand (0.75 %)

Management fee

0.45 %

0.23 %


Key Summary

CURE

IHD

Issuer

Global X

iShares

Tracking index

S&P Biotechnology Select Industry

S&P/ASX Dividend Opportunities Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.23 %

Price

$52.68

$14.64

Size

$36.301 million

$313.421 million

10Y return

N/A

2.23 %

Annual distribution yield (5Y)

4.24 %

7.42 %

Market

ASX

ASX

First listed date

12/11/2018

09/12/2010

Purchase fee

$6.50

$6.50


Community Stats

CURE

IHD

Popularity

Low

Low

Pearlers invested

83

27

Median incremental investment

$619.50

$644.56

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$1,357.92

Average age group

> 35

> 35


Pros and Cons

CURE

IHD

Pros

  • Higher exposure to US market

  • Higher exposure to AU market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to AU market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

  • Lower exposure to US market

CURE

IHD

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home